Mergers & AcquisitionsMedium•6 October 2026•
1 min read
Repligen Completes BioLife Solutions Acquisition to Expand Cell Therapy Reach
Key Facts
1Repligen Corporation has completed its acquisition of BioLife Solutions to expand its presence in the cell and gene therapy market.
2BioLife stockholders received $11.25 in cash and 0.1442 shares of Repligen common stock per share held.
Repligen Corporation has completed its acquisition of BioLife Solutions to expand its presence in the cell and gene therapy market. GlobeNewswire reported that BioLife stockholders received $11.25 in cash and 0.1442 shares of Repligen common stock per share held, integrating BioLife’s biopreservation media and cell processing tools into Repligen’s bioprocessing portfolio.
RGEN closed at $189.50 on October 5, 2026, while BLFS closed at $38.61 on the same date. The merger aims to create a high-margin consumables business with recurring revenue by leveraging Repligen’s global commercial reach to scale BioLife’s products, which currently support 18 commercially approved therapies.